Sunho Biologics Gets Green Light For Downsized IPO
Sunho Biologics Gets Green Light For Downsized IPO
Sunho Biologics獲准縮減首次公開募股
Key Takeaways:
關鍵要點：
Sunho Biologics has no revenue or licensing income to draw on, making a loss of 133 million yuan last year as all its products remain at the R&D or clinical stage
The company is rumored to be targeting just $50 million in proceeds, only a third of the $150 million it was thought to be seeking in its first IPO attempt last year
Sunho Biologics沒有收入或許可收入可供提取，由於其所有產品仍處於研發或臨床階段，去年虧損1.33億元人民幣
有傳言說，該公司的目標收益僅爲5000萬美元，僅佔去年首次公開募股時預計要尋求的1.5億美元的三分之一
By Fai Pui
作者：Fai Pei
The market conditions may be dire, but Chinese drug developer Sunho Biologics Inc. needs the cash.
市場狀況可能很糟糕，但中國藥物開發商Sunho Biologics Inc.需要現金。
The loss-making biotech has secured the green light for an IPO, but the Hong Kong market...
這家虧損的生物技術公司已經爲首次公...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。